Rotterdam Erasmus MC, in 2013 ARTPred obtained an exclusive patent license from Erasmus MC, the initial inventors of the correlation between the urinary microbiome and the outcome of IVF.

Healthy population and excellent healthcare. This is what Erasmus MC stands for. Conducting groundbreaking work, pushing boundaries, and leading the way in research, education, and healthcare. Erasmus MC employs practical thinkers, driven professionals with a can-do mentality who use their expertise to expand the pool of knowledge about health and disease, who improve diagnostics and treatment, and who continually look for ways to innovate. Their commitment helps Erasmus MC to help their patients and others with a healthcare need even more effectively, and enables us to keep healthy people healthy for longer.



MicrobiomeMicrobiome Ltd and IS-diagnostics Ltd are ARTPred’s partners for analysis, certification, manufacturing and distribution. 

Microbiome is a spin-off company of the VU medical center in Amsterdam and is active in the discovery, development, manufacturing and marketing of innovative molecular characterizations. Since the establishmentof Microbiome in microbiological techniques, tools, systems, kits and 2005, this company established her name as a business partner for several multinational companies, for example Philips, Roche, bioMérieux, Colgate-Palmolive.

IS-DiagnosticsIS-diagnostics is a young company focusing on a new generation of clinical diagnostics. IS-diagnostics combines cutting-edge IT solutions with innovative chemistry to bring the next generation of clinical diagnostics to laboratories today.



NGIThe Netherlands Genomics Institute (NGI) and ZonMw have awarded the NGI preseed grant to ARTPred in 2014.

NGI creates societal and economic value from genomics through a network of large-scale Genomics Centres that work on targeted programmes. These centres are consortiums of universities, research institutes, industry and societal organisations. Excellent research, state-of-the-art technology infrastructure, societal embedding of genomics and a stimulating environment for research talent remain key elements of the NGI strategy. The main shift in focus is towards valorisation, i.e., creating added value from genomics research and application gets top priority.



STWSTW has awarded the valorisation grant phase 1 + phase 2 to ARTPred in 2014.

Technology Foundation STW realises the transfer of knowledge between the technical sciences and users. It does this by funding excellent technical scientific research and by bringing researchers and users together in each project.



RedMedTEchThe RedMedTech Discovery Fund has supported ARTPred’s funding proposal in 2014.

RedMedTech Ventures is a support program for Life Science & Health start ups, funded by the Dutch provinces of Gelderland, Overijssel and Noord-Brabant. Executive partners are: Health Valley, Radboud UMC, Isala Clinics, Rijnstate, Medtech Partners, Pivot Park, TU Eindhoven, Saxion Hogescholen, The Decision Group and the Development Agency of the East part of the Netherlands (OOST N.V.).



In collaboration with national and international IVF centers ARTPred is initiating an international multicenter clinical trial to validate the results of the first clinical trial by Erasmus MC.